Application of the Lung Immune Prognostic Index From Research to Clinical Practice-Reply

JAMA Oncol. 2020 Feb 1;6(2):300-301. doi: 10.1001/jamaoncol.2019.5157.

Authors

Dickran Kazandjian^{1

2}, Yutao Gong¹, Gideon M Blumenthal¹

Affiliations

¹ Oncology Center of Excellence and Office of Hematology and Oncology Products, US Food and Drug Administration, Silver Spring, Maryland.
² Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

PMID: 31774473
DOI: 10.1001/jamaoncol.2019.5157

No abstract available

Publication types

Letter
Kommentar

MeSH terms

Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung*
Humans
Lung
Lung Neoplasms*
Prognosis

Substances

Biomarkers, Tumor